卡维地洛治疗慢性充血性心力衰竭临床疗效及安全性研究  

Clinical Efficacy and Safety of Carvedilol in the Treatment of Chronic Congestive Heart Failure

作　　者：张永生[1] 楚立云[1] 时春华[1] ZHANG Yongsheng CHU Liyun(Sill Chunhua Second Department of Cadre Ward, 401 Hospital of Chinese People＇s Liberation Army, Qingdao Shandong 266000, China)

机构地区：[1]中国人民解放军第401医院干部病房二科,山东青岛266000

出　　处：《中国继续医学教育》2017年第9期190-191,共2页China Continuing Medical Education

摘　　要：目的探讨卡维地洛治疗慢性充血性心力衰竭患者的临床疗效及安全性。方法将本院于2014年6月—2016年6月收治的112例慢性充血性心力衰竭患者作为研究对象,随机分为两组各56例,对照组患者采用常规治疗方式,观察组患者在此基础上增加卡维地洛治疗,观察比较两组患者临床疗效及安全性。结果观察组与对照组患者治疗有效率分别为98.22%、82.93%,不良反应发生率分别为5.36%、3.57%,疗效差异具有统计学意义(P<0.05),不良反应差异无统计学意义(P>0.05)。结论卡维地洛治疗慢性充血性心力衰竭临床疗效显著,且安全性较高,利于改善患者心功能。Objective To investigate the clinical efficacy and safety of carvedilol in the treatment of chronic congestive heart failure. Methods 112 patients with chronic congestive heart failure who were enrolled in this study from June 2014 to June 2016 were randomly divided into two groups： 56 patients in each group. The patients in the control group were treated with conventional treatment. On the basis of this, increased carvedilol treatment in the observation group, observed and compared the two groups of patients with clinical efficacy and safety. Results The effective rates were 98.22% and 82.93% in the observation group and the control group respectively. The incidence of adverse reactions was 5.36% and 3.57% respectively. The difference was statistically significant in curative effect （P〈0.05）, and there was no significant difference in adverse reactions （P 〉 0.05）. Conclusion Carvedilol treatment of chronic congestive heart failure clinical efficacy is significant, and high safety, which will help improve the patient＇s cardiac function.

关 键 词：卡维地洛 慢性充血性心力衰竭 临床疗效 

分 类 号：R541.6[医药卫生—心血管疾病]